| LARIMAR THERAP.I. DL-,001 |
| USA |
| Gesundheit |
| US5171251003 / A2P5PP |
| ZA71 (Frankfurt) |
| FRA:ZA71, ETR:ZA71, ZA71:GR |
| - |
| https://larimartx.com/ |
|
Larimar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its proprietary cell-penetrating peptide technology platform. This platform enables intracellular delivery of missing..
>Volltext.. |
| 333.99 Mio. EUR |
| 164.02 Mio. EUR |
| - |
| -151.18 Mio. EUR |
| -145.82 Mio. EUR |
| -1.83 EUR |
| 3.32 Mio. EUR |
| 156.28 Mio. EUR |
| -115.32 Mio. EUR |
| 4.2 |
| - |
| -63.23% |
| - |
| - |
| - |
| - |
| LARIMAR |
| 29.06.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|